Need proof that pharma doesn’t give a damn about patients or employees? Consider the following:
1ne: Allergan is letting go more than 1,000 staffers across its commercial team and other areas, it said in a Wednesday financial filing. It’s also axing about 400 jobs that aren’t currently filled, for a total job-cutting toll of 1,400.
2wo: Drug and device makers accounted for more than $900 million of $3.7 billion in settlements and judgments from civil cases involving fraud and false claims against the government in the fiscal year ending Sept. 30, 2017 .
3hree: A handful of drug companies rang in 2018 with price hikes that easily surpass inflation , but stay conspicuously below double digits including:
AbbVie’s blockbuster Humira: 9.7%
Amgen’s arthritis medicine Enbrel: 9.7%
Allergan’s dry eye drug Restasis: 9.5%
Insys Therapeutics’ opioid spray Subsys: 9.5%
Biogen’s multiple sclerosis drug Tecfidera: 8%
18 years of Pharma marketing experience through development, launch and measurement. Thought leader journalist who has articles appear in the Wall Street Journal, Pharmaforum, Ad Age, and STAT News
1ne: Allergan is letting go more than 1,000 staffers across its commercial team and other areas, it said in a Wednesday financial filing. It’s also axing about 400 jobs that aren’t currently filled, for a total job-cutting toll of 1,400.
2wo: Drug and device makers accounted for more than $900 million of $3.7 billion in settlements and judgments from civil cases involving fraud and false claims against the government in the fiscal year ending Sept. 30, 2017 .
3hree: A handful of drug companies rang in 2018 with price hikes that easily surpass inflation , but stay conspicuously below double digits including:
AbbVie’s blockbuster Humira: 9.7%
Amgen’s arthritis medicine Enbrel: 9.7%
Allergan’s dry eye drug Restasis: 9.5%
Insys Therapeutics’ opioid spray Subsys: 9.5%
Biogen’s multiple sclerosis drug Tecfidera: 8%